Clinical Trial Update: Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the impact of PCSK9 inhibitors on coronary plaque composition and vulnerability using optical coherence tomography.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Coronary Artery Disease

Drugs mentioned

• PCSK9 inhibitors

Snippet

Sponsor: Beijing Anzhen Hospital | Conditions: Randomized Controlled Trials | Phase 4 | Status: COMPLETED